Peptide Receptor Radionuclide Therapy for a Phosphaturic Mesenchymal Tumor.

Häfliger, Simon; Seidel, Ann-Katrin; Schoch, Eric; Reichmann, Jan; Wild, Damian; Steinmann-Schwager, Stephanie; Pless, Miklos

Häfliger, Simon; Seidel, Ann-Katrin; Schoch, Eric; Reichmann, Jan; Wild, Damian; Steinmann-Schwager, Stephanie; Pless, Miklos.

Afiliación

Häfliger S; Department of Medical Oncology, Kantonsspital Winterthur, Winterthur, Switzerland.
Seidel AK; Department of Medical Oncology, Kantonsspital Winterthur, Winterthur, Switzerland.
Schoch E; Department of Radiology, Kantonsspital Winterthur, Winterthur, Switzerland.
Reichmann J; Division of Nuclear Medicine, University Hospital Basel, Basel, Switzerland.
Wild D; Division of Nuclear Medicine, University Hospital Basel, Basel, Switzerland.
Steinmann-Schwager S; Hausärzte am Bahnhofplatz, General Medicine Office, Winterthur, Switzerland.
Pless M; Department of Medical Oncology, Kantonsspital Winterthur, Winterthur, Switzerland.

Case Rep Oncol ; 13(3): 1373-1380, 2020.

Article en En | MEDLINE | ID: mdl-33442358

Palabras clave

DOTATOC; Peptide receptor radionuclide therapy; Phosphaturic mesenchymal tumor; Radiofrequency ablation; Tumor-induced osteomalacia

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Case Rep Oncol Año: 2020 Tipo del documento: Article País de afiliación: Suiza Pais de publicación: Suiza

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google